Welcome Guest

Abstract
Add to Favorites
  • Volume 4
  •  Issue 2
  • Publication Date: September 2005


Second-Line Chemotherapy for Prostate Cancer: Patient Characteristics and Survival


Kathleen W. Beekman, Mark T. Fleming, Howard I. Scher, Susan F. Slovin, Nicole M. Ishill, Glenn Heller, W. Kevin Kelly

Purpose: First-line chemotherapy with docetaxel in patients with progressive castrate metastatic prostate cancer has been shown to improve overall survival compared with mitoxantrone-based therapies. The use and outcomes of chemotherapy after first-line antimicrotubule-based therapy have not been well described. Patients and Methods: Patients with progressive castrate metastatic prostate cancer enrolled on an antimicrotubule-based protocol for treatment were followed to determine their baseline characteristics and outcomes with second- or third-line systemic therapy. Results: Of 108 patients treated with antimicrotubule-based therapy, 81% received second-line therapy, and 40% received third-line therapies. Corresponding prostate-specific antigen (PSA) decreases = 50% were observed in 72%, 15%, and 22% of patients. Median survival times from the start of first-, second-, and third-line therapy were 21 months (95% confidence interval [CI], 18-25 months), 13 months (95% CI, 10-15 months) and 12 months (95% CI, 9-19 months). Significant prognostic indicators for survival in the second-line setting include pretreatment PSA level, alkaline phosphatase level, and performance status. Patients not fit to receive second-line therapy were more symptomatic with first-line therapy, as illustrated by a greater need for narcotic therapy (67% vs. 15%) and palliative radiation therapy after first-line therapy (57% vs. 10%) in lieu of second-line systemic therapy. Conclusion: Eighty percent of patients received second-line chemotherapy, with a median survival of 12 months from the start of second-line treatment. Although only 40% received third-line chemotherapy, median survival was similar to that of patients in the second-line setting. Our data show that patients who initiate chemotherapy with symptoms are more likely to require palliative radiation therapy rather than chemotherapy as second-line therapy. A sequential or continuous administration of therapy may optimize the care of this subset of symptomatic patients.

Key words: Alkaline phosphates, Clinical trials, Metastatic disease, Taxanes



  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  16. pintarbersamamedan.org
  17. https://pintarbersamamanado.org
  18. https://pintarbersamasorong.org/dana
  19. DATA HK
  20. HK LOTTO
  21. PENGELUARAN HK
  22. DATA HK
  23. TOGEL HK
  24. PENGELUARAN SGP
  25. TOGEL SDY
  26. TOGEL HONGKONG
  27. PENGELUARAN SGP
  1. KELUARAN SGP
  2. TOGEL